210 related articles for article (PubMed ID: 18499554)
1. HIV-associated facial lipoatrophy--review of current therapy options.
Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
[TBL] [Abstract][Full Text] [Related]
2. Long-term complications of antiretroviral therapy: lipoatrophy.
Waters L; Nelson M
Int J Clin Pract; 2007 Jun; 61(6):999-1014. PubMed ID: 17504362
[TBL] [Abstract][Full Text] [Related]
3. Management options for facial lipoatrophy.
Cofrancesco J; Brown T; Martins CR
AIDS Read; 2004 Dec; 14(12):639-40, 645-50. PubMed ID: 15619779
[TBL] [Abstract][Full Text] [Related]
4. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
Walther RA
Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
[TBL] [Abstract][Full Text] [Related]
5. Restorative interventions for HIV facial lipoatrophy.
Carey D; Liew S; Emery S
AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
[TBL] [Abstract][Full Text] [Related]
6. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
8. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
Reytan N; Rzany B
J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
[TBL] [Abstract][Full Text] [Related]
9. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
Parruti G; Toro GM
BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
[TBL] [Abstract][Full Text] [Related]
10. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
11. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR; Hay P
J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
[TBL] [Abstract][Full Text] [Related]
13. Treatment of facial lipoatrophy via autologous fat transfer.
Cohen G; Treherne A
J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
[TBL] [Abstract][Full Text] [Related]
14. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
[TBL] [Abstract][Full Text] [Related]
15. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
16. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
17. Treatment of facial lipoatrophy in HIV-infected patients.
Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
20. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
